DK3211005T3 - Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme - Google Patents

Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme Download PDF

Info

Publication number
DK3211005T3
DK3211005T3 DK17159699.2T DK17159699T DK3211005T3 DK 3211005 T3 DK3211005 T3 DK 3211005T3 DK 17159699 T DK17159699 T DK 17159699T DK 3211005 T3 DK3211005 T3 DK 3211005T3
Authority
DK
Denmark
Prior art keywords
msrv
therapeutic use
associated diseases
specific ligand
ligand
Prior art date
Application number
DK17159699.2T
Other languages
English (en)
Inventor
Corinne Bernard
Alois Bernhardt Lang
Hervé Perron
Jean-Baptiste Bertrand
Original Assignee
Geneuro Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneuro Sa filed Critical Geneuro Sa
Application granted granted Critical
Publication of DK3211005T3 publication Critical patent/DK3211005T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK17159699.2T 2008-07-08 2009-07-08 Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme DK3211005T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12961308P 2008-07-08 2008-07-08
US20258109P 2009-03-13 2009-03-13
US21318909P 2009-05-15 2009-05-15
EP09780311.8A EP2315777B1 (en) 2008-07-08 2009-07-08 Therapeutic use of specific ligand in msrv associated diseases

Publications (1)

Publication Number Publication Date
DK3211005T3 true DK3211005T3 (da) 2021-06-07

Family

ID=41165692

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17159699.2T DK3211005T3 (da) 2008-07-08 2009-07-08 Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme

Country Status (24)

Country Link
US (4) US8715656B2 (da)
EP (2) EP3211005B1 (da)
JP (3) JP6058264B2 (da)
KR (1) KR101682040B1 (da)
CN (1) CN102143975B (da)
AU (1) AU2009268025B2 (da)
BR (1) BRPI0915667B8 (da)
CA (1) CA2729869C (da)
CY (2) CY1119185T1 (da)
DK (1) DK3211005T3 (da)
EA (1) EA024655B1 (da)
ES (2) ES2633965T3 (da)
HK (2) HK1158232A1 (da)
HR (2) HRP20171067T1 (da)
HU (2) HUE033803T2 (da)
IL (1) IL210204A (da)
LT (2) LT2315777T (da)
MX (1) MX2010014319A (da)
NZ (1) NZ590515A (da)
PL (2) PL2315777T3 (da)
PT (2) PT3211005T (da)
SI (2) SI2315777T1 (da)
WO (1) WO2010003977A1 (da)
ZA (1) ZA201100446B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174053A1 (en) 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
ES2633965T3 (es) * 2008-07-08 2017-09-26 Geneuro Sa Uso terapéutico de ligando específico en enfermedades asociadas a MSRV
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
UA119032C2 (uk) * 2012-10-02 2019-04-25 Женеро Са Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w
EP2949342A1 (en) * 2014-05-28 2015-12-02 Geneuro SA Antiretroviral drug targeting human endogenous retrovirus
SG11201802698XA (en) * 2015-10-29 2018-05-30 Hoffmann La Roche Transgenic rabbit with common light chain
JP2018028538A (ja) * 2016-08-12 2018-02-22 公立大学法人名古屋市立大学 統合失調症とその関連疾患の診断用マーカー及びその使用
WO2019201908A1 (en) 2018-04-17 2019-10-24 Geneuro Sa Method for the detection of the soluble hydrophilic oligomeric form of herv-w envelope protein
EP3916015A1 (en) * 2020-05-28 2021-12-01 Geneuro SA Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases
CN113940993B (zh) * 2021-12-20 2022-02-22 深圳万可森生物科技有限公司 一种鲈鱼弹状病毒g2-2m亚单位疫苗及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
BR9007588A (pt) 1989-08-09 1992-06-30 Dekalb Plant Genetics Processo e composicoes para a producao de plantas monocotiledoneas ferteis,transformadas de maneira estavel,e suas celulas
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2734842B1 (fr) 1995-06-02 1998-02-27 Rhone Poulenc Agrochimie Sequence adn d'un gene de l'hydroxy-phenyl pyruvate dioxygenase et obtention de plantes contenant un gene de l'hydroxy-phenyl pyruvate dioxygenase, tolerantes a certains herbicides
FR2736926B1 (fr) 1995-07-19 1997-08-22 Rhone Poulenc Agrochimie 5-enol pyruvylshikimate-3-phosphate synthase mutee, gene codant pour cette proteine et plantes transformees contenant ce gene
WO2001031021A1 (en) 1999-10-28 2001-05-03 Universite De Geneve Multiple sclerosis-related superantigen
EP1629013B1 (en) * 2003-05-31 2018-01-24 Amgen Research (Munich) GmbH Pharmaceutical composition comprising a bispecific antibody specific for epcam
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w
EP2314317A3 (en) 2004-07-09 2011-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
EP1801208A4 (en) 2004-09-06 2009-04-01 Kirin Pharma Kk ANTI-A33 ANTIBODIES
WO2006067847A1 (ja) * 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
EP1921137A4 (en) 2005-06-21 2011-01-26 Med & Biological Lab Co Ltd ANTIBODIES WITH INHIBITOR EFFECT ON THE FORMATION OF AMYLOID FIBRILLES
FR2912314B1 (fr) * 2007-02-09 2012-08-03 Geneuro Sa Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
ES2633965T3 (es) * 2008-07-08 2017-09-26 Geneuro Sa Uso terapéutico de ligando específico en enfermedades asociadas a MSRV

Also Published As

Publication number Publication date
PT2315777T (pt) 2017-07-25
CY1124281T1 (el) 2022-07-22
US20180057569A1 (en) 2018-03-01
CA2729869A1 (en) 2010-01-14
US9550824B2 (en) 2017-01-24
ZA201100446B (en) 2012-01-25
IL210204A (en) 2015-03-31
US20140220026A1 (en) 2014-08-07
CN102143975B (zh) 2014-12-31
BRPI0915667B1 (pt) 2020-10-13
IL210204A0 (en) 2011-03-31
BRPI0915667B8 (pt) 2021-05-25
BRPI0915667A2 (pt) 2017-01-17
US9815888B2 (en) 2017-11-14
ES2875762T3 (es) 2021-11-11
HUE054712T2 (hu) 2021-09-28
AU2009268025A1 (en) 2010-01-14
CY1119185T1 (el) 2018-02-14
HUE033803T2 (en) 2018-01-29
SI2315777T1 (sl) 2017-09-29
ES2633965T3 (es) 2017-09-26
MX2010014319A (es) 2011-05-19
HRP20171067T1 (hr) 2017-10-06
PL2315777T3 (pl) 2017-10-31
LT2315777T (lt) 2017-10-25
KR20110031969A (ko) 2011-03-29
US10059758B2 (en) 2018-08-28
SI3211005T1 (sl) 2021-06-30
CA2729869C (en) 2018-02-13
JP6109869B2 (ja) 2017-04-05
PT3211005T (pt) 2021-06-15
US20110243962A1 (en) 2011-10-06
WO2010003977A1 (en) 2010-01-14
EP2315777A1 (en) 2011-05-04
NZ590515A (en) 2013-01-25
EA201100160A1 (ru) 2011-08-30
EA024655B1 (ru) 2016-10-31
KR101682040B1 (ko) 2016-12-02
US8715656B2 (en) 2014-05-06
AU2009268025B2 (en) 2014-07-31
PL3211005T3 (pl) 2021-11-29
JP6495361B2 (ja) 2019-04-03
HK1158232A1 (en) 2012-07-13
JP2015157812A (ja) 2015-09-03
JP6058264B2 (ja) 2017-01-11
HK1243436A1 (zh) 2018-07-13
EP3211005B1 (en) 2021-03-17
CN102143975A (zh) 2011-08-03
JP2011527887A (ja) 2011-11-10
LT3211005T (lt) 2021-08-25
EP2315777B1 (en) 2017-04-26
US20170107274A1 (en) 2017-04-20
EP3211005A1 (en) 2017-08-30
HRP20210892T1 (hr) 2021-11-26
JP2017158550A (ja) 2017-09-14

Similar Documents

Publication Publication Date Title
CY2020043I1 (el) Παγιδες gdf για χρηση στη θεραπευτικη αντιμετωπιση της αναιμιας
DK3211005T3 (da) Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
BRPI0916931A2 (pt) agentes terapêuticos
BRPI0819073A2 (pt) fralda descartável
DK2144905T3 (da) Terapeutiske midler
DK2035369T3 (da) Terapeutiske
BRPI0819071A2 (pt) fralda descartável
BRPI0910534A2 (pt) terapia antiviral
BRPI0917684A2 (pt) método terapêutico homeopático
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
SMT201600041B (it) Agenti terapeutici 713
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
BRPI0909764A2 (pt) compostos terapêuticos
DK2103321T3 (da) Engangssprøjte
BRPI0906879A2 (pt) Compostos terapêuticos
DK2315777T3 (da) Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
BRPI0911543A2 (pt) arilciclopentenos substituídos como agentes terapêuticos
ES1065138Y (es) Chancla desechable
FI20085971A0 (fi) Betaiinin käyttö
ES1067268Y (es) Bufanda con aplicacion terapeutica
DK2203170T3 (da) Novel therapeutic uses of adrenergic alfuzosine
FI20080332A0 (fi) Terapeuttisia molekyylejä
DOS2009000118S (es) Pañal desechable